

# Subjecting the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) to control measures

2017/0340(NLE) - 02/02/2018 - Legislative proposal

**PURPOSE:** to subject the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) to control measures.

**PROPOSED ACT:** Council Implementing Decision.

**ROLE OF THE EUROPEAN PARLIAMENT:** the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

**BACKGROUND:** the risk assessment report on **ADB-CHMINACA** prepared by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and sent to the Commission and the Council on 14 November 2017 concludes that this substance - available in the Union since at least August 2014 and detected in 17 Member States - is a **synthetic cannabinoid** with similar effects to those of THC, but with additional life-threatening toxicity. More than **630 seizures** have been made within the Union.

ADB-CHMINACA is typically sold in small and wholesale amounts in head shops, branded as a legal high as smoking mixtures or as powder, as well as on the internet, branded as a legal replacement for cannabis. It has no recognised human or veterinary medical use in the Union.

Three Member States have reported **13 deaths** associated with ADB-CHMINACA. In addition, one Member State reported **three acute non-fatal intoxications** associated with the substance.

The available evidence and information on the **health and social risks** that the substance poses provides sufficient grounds for subjecting ADB-CHMINACA to control measures across the Union.

**CONTENT:** the draft Council decision aims to **subject the new psychoactive substance ADB-CHMINACA to the control measures** and criminal penalties provided for by Member States' legislation, in accordance with their obligations under the United Nations Single Convention on Narcotic Drugs of 1971.

*For more details, see the summary of the Commission's initial legislative proposal dated 18.12.2017.*